IMPROVEMENT in ERADICATION of H-PYLORI INFECTION

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

195 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-15

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Efficacy in terms of H pylori eradication of clarithromycin based sequential therapy with lactobacillus is better than sequential based therapy alone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Eradication of Helicobacter Pylori With a Lactobacillus Reuteri Strain Plus Proton Pump Inhibitor

NCT03404440

Helicobacter Pylori Infection

COMPLETED NA

The Effect of Lactobacillus Reuteri Probiotic as an Adjunct Treatment for Helicobacter Pylori Infection in Adults

NCT05399862

Helicobacter Pylori Infection

COMPLETED NA

Lactobacillus Reuteri ProGastria in Helicobacter Pylori-infected Adult Subjects on Proton Pump Inhibitors

NCT01456728

Helicobacter Pylori Infection

COMPLETED PHASE3

Lactobacillus Reuteri Strain Combination in Children Treated With PPI

NCT05484128

Gastric Lesion Proton Pump Inhibitor Adverse Reaction Probiotic

RECRUITING NA

The Effects Probiotic Has on Gastromicroecology and Combined With Quadruple Regimen for H Pylori Infection

NCT03377933

Efficacy Gastric Microbiota Safety

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Data Collection:

Subjects attending outpatient in department of Gastroenterology meeting the inclusion \& exclusion criteria in Liaquat National Hospital, Karachi with H. pylori related chronic gastritis with/without peptic ulcers on endoscopy \& gastric biopsy (histopathology) or Stool for H. pylori antigen +ve, or Rapid urease test +ve or Positive Urea Breath Test as per operational definition will be included. For all patients included in this study, we will collect the following information age, gender, duration of the disease.Patients will be divided into two groups randomly, group A and B.In group A (case) patients along with standard sequential therapy :

* Amoxil 1000 mg twice daily for first 5 days
* clarithromycin 500 mg twice daily plus Tinidazole 500 mg twice daily for next 5 days with addition of lactobacillus R 100 mg twice daily in capsule form will be given for 2 weeks. While group B (control) will include patients who have already received standard sequential therapy which is
* Amoxil 1000mg twice daily for first 5 days
* Clarithromycin 500 mg twice daily plus Tinidazole 500 mg twice daily for next 5 days After completion of 6 weeks of proton pump inhibitors (PPI), it will be stopped. As per our protocol for all patients , after 1-2 weeks of stopping PPI stool sample will be collected and will be sent to the laboratory of the institute for helicobacter pylori stool antigen (HPSA).This test is performed as routine to check the success of eradication therapy. H. pylori eradication will be achieved if post treatment HPSA is negative. All demography, clinical history will be recorded by a principal investigator on a predesigned proforma, informed written consent will be taken before enrolment. Exclusion criteria will be followed strictly to avoid confounding variables.

MATERIAL AND METHODS

Study design:

Randomized control study.

Setting:

Study was conducted in Out Patients Department of Gastroenterology, Liaquat National Hospital, Karachi.

Duration: One year after approval of synopsis from hospital ethics committee.

Sample size:

Sample size: Sample size was calculated on the basis of the following eradication rate of H. Pylori with clarithromycin based sequential therapy regimen was= 76%(no relevant statistics available regarding combination of clarithromycin based sequential therapy regimen with lactobacillus Reuteri) Confidence level=95% Bond on error= 6% Sample size (n) = 195 no: of H. Pylori positive Patients in each group, with total of 390 patients Formula n= z2p (1-P) /d2

Inclusion criteria:

* Patients between 18 years to 60 years of age.
* Either gender
* Patients having H. pylori related chronic gastritis with/without peptic ulcers on endoscopy \& gastric biopsy (histopathology) or Stool for H. pylori antigen +ve , or Rapid urease test +ve

Exclusion criteria:

* Pregnant women
* End stage renal disease (GFR \<15 mL/min/)
* Chronic Liver Disease

Data analysis:

Statistical package for Social Sciences (SPSS version 22) was used for data analysis. Frequencies and percentages were computed for qualitative variables like gender, post eradication HPSA (negative/positive). Quantitative variables will be presented as mean ± standard deviation for age and duration of dyspepsia. Effect modifiers like age, gender, duration of dyspepsia were controlled through stratification. Post stratification Chi-square test was used. P value ≤0.05 was considered as significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Helicobacter Pylori Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ERADICATION of H-PYLORI INFECTION with ADDITION of LACTOBACILLUS REUTERI

In experimental group, patients receiving clarithromycin based sequential therapy with LACTOBACILLUS REUTERI

Group Type EXPERIMENTAL

Lactobacillus Reuteri Probiotic

Intervention Type DRUG

Experimental group receiving Lactobacillus Reuteri Probiotic with sequential therapy

ERADICATION of H-PYLORI INFECTION without LACTOBACILLUS REUTERI

control group included patients who received clarithromycin based sequential therapy alone

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lactobacillus Reuteri Probiotic

Experimental group receiving Lactobacillus Reuteri Probiotic with sequential therapy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

sequential therapy with Lactobacillus Reuteri Probiotic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients between 18 years to 60 years of age.
* Either gender
* Patients having H. pylori related chronic gastritis with/without peptic ulcers on endoscopy \& gastric biopsy (histopathology) or Stool for H. pylori antigen +ve , or Rapid urease test +ve